Drug Profile
Recombinant lymphotoxin alpha derivative - Shanghai Fudan-Zhangjiang
Alternative Names: rhLT; rhLT28-171; rhLTα-DaLatest Information Update: 26 Jun 2015
Price :
$50
*
At a glance
- Originator Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
- Class Antihyperglycaemics; Antineoplastics; Antivirals; Cytokines; Lymphokines; Tumour necrosis factors
- Mechanism of Action Tumour necrosis factor receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Oesophageal cancer
Most Recent Events
- 28 Mar 2011 Phase-II clinical trials in Oesophageal cancer in China (IV)
- 30 Sep 2007 Phase-I clinical trials in Solid tumours in China (IV)